The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): A systematic review

Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review

“…Significant deterioration of general SXF over time before and after the treatment in VC patients was reported in 2 studies, assessed by self-designed nonvalidated questionnaire and the general sex life domain of the ePAQ-PF (Tables 2 and 3). 18,39 Furthermore, in one study, adjuvant inguinal RT was negatively associated with the ability to achieve orgasm (P = 0.01). 21 Factors associated with posttreatment sexual dysfunction included ILND, 27 older age 18,21,22,27 poor performance status, a history of depression, and preoperative psychosexual difficulties.…”

Gynecological cancer survivors’ health behaviors and their associations with quality of life

“…Gynecological cancers account for approximately 18% of all female cancers worldwide [1], and are a major source of mortality and morbidity [2]. A range of site-specific difficulties can persist after treatment, including sexual problems (12%), bladder dysfunction (11%), vaginal problems (e.g., recurrent infections) (10%), and lower limb lymphedema (10%) [3,4].…”

Interleukin 17 Induces Up-Regulation of Chemokine and Cytokine Expression Via Activation of the Nuclear Factor κB and Extracellular Signal–Regulated Kinase 1/2 Pathways in Gynecologic Cancer Cell Lines

“…7 Some observations suggest that IL-17 may be important in gynecological cancers. Interleukin 17 has been implicated in tumor vascularization of 2 of the 3 most common gynecological cancers, cervical and ovarian.…”